Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-29, Stock:LLY, The news for the past five days is as follows:
2019-03-22: NEWS1: Eli Lilly (LLY) Stock Moves -0.01%: What You Should Know.NEWS2: After Hours Most Active for Mar 22, 2019 :  AEG, MS, QQQ, ELAN, LLY, VIPS, MAR, F, JD, INTC, MSFT, AMD.NEWS3: After Hours Most Active for Mar 22, 2019 :  AEG, MS, QQQ, ELAN, LLY, VIPS, MAR, F, JD, INTC, MSFT, AMD.NEWS4: Bull of the Day: DexCom (DXCM).NEWS5: Bull of the Day: DexCom (DXCM).NEWS6: Bull of the Day: DexCom (DXCM).NEWS7: Better Buy: AbbVie vs. Eli Lilly.NEWS8: Better Buy: AbbVie vs. Eli Lilly.NEWS9: Better Buy: AbbVie vs. Eli Lilly.
2019-03-25: NEWS1: Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth.NEWS2: PRESS DIGEST - Wall Street Journal - March 25.
2019-03-26: NEWS1: Better Buy: Eli Lilly vs. GlaxoSmithKline.NEWS2: Lilly and ImmuNext Announce Licensing and Research Collaboration.NEWS3: Were Hedge Funds Right About Eli Lilly and Company (LLY)?.NEWS4: Health Care Select Sector SPDR Fund Experiences Big Inflow.NEWS5: Health Care Select Sector SPDR Fund Experiences Big Inflow.NEWS6: Eli Lilly and Company (NYSE:LLY): What’s The Analyst Consensus Outlook?.
2019-03-27: NEWS1: 5 Cancer-Fighting Stocks to Boost Portfolio Gains.NEWS2: 5 Cancer-Fighting Stocks to Boost Portfolio Gains.NEWS3: 5 Cancer-Fighting Stocks to Boost Portfolio Gains.NEWS4: Lilly (LLY) Signs New Immunology Deal With Private Biotech.NEWS5: Lilly (LLY) Signs New Immunology Deal With Private Biotech.NEWS6: Lilly (LLY) Signs New Immunology Deal With Private Biotech.NEWS7: The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO.NEWS8: Better Buy: Eli Lilly vs. GlaxoSmithKline.
2019-03-28: NEWS1: Cramer's lightning round: Don't buy this low-reward, high-risk stock.

Answer: Rise